Sponsored Content
Sponsored by Sumitomo Pharma America, Inc.
Clinical Utility of GEMTESA® (vibegron) in Diverse Managed OAB Populations
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CagriSema reduces HbA1c, weight across T2D spectrum in REIMAGINE trials | ADA 2026
2
Lee Kaplan, M.D., discusses the metabolic case for survodutide | ADA 2026
3
Nearly half of older adults with metastatic lung cancer never receive systemic therapy, study finds
4
Machine learning model predicts T2D risk up to 10 years before onset
5